Applying Quality by Design for Extended Release Hydrophilic Matrix Tablets - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Applying Quality by Design for Extended Release Hydrophilic Matrix Tablets
This study examines the effect and interaction of variations in hypromellose physicochemical properties.


Pharmaceutical Technology
Volume 36, Issue 10, pp. 106-116

References

1. L.X. Yu, Pharm. Res. 25(4), 781–791 (2008).

2. T.D. Cabelka et al., "Application of Quality by Design Principles to the Formulation of aHydrophilic Matrix Tablet of a High Dose/High Solubility Drug," presented at the AAPS Annual Meeting (Los Angeles, 2009).

3. T.D Cabelka et al., "Application of Quality by Design Principles to the Formulation of Extended-Release Propranolol Hydrochloride Hydrophilic Matrix Tablets," presented at the AAPS Annual Meeting (New Orleans, 2010).

4. H. Deng et al., "Application of Quality by Design Principles to the Formulation of Extended-Release Theophylline Hydrophilic Matrix Tablets," presented at the CRS Annual Meeting and Exposition (National Harbor, Maryland, 2011).

5. A.S. Rathore and H. Winkle, Nature Biotechnol. 27 (1) 26–34 (2009).

6. ICH, ICH Q8(R2) Pharmaceutical Development (2009).

7. USP 30–NF 25, "USP Monographs: Hypromellose," online, http://www.uspnf.com/, accessed May 10, 2008.

8. J.E. Hogan, Drug Dev. Ind. Pharm. 15 (6), 975–1999 (1989).

9. P. Gao et al., J. Pharm. Sci. 85 (7), 732–740 (1996).

10. M. Levina and A.R. Rajabi-Siahboomi, J. Pharm. Sci. 93 (11), 2746–2754 (2004).

11. K. Mitchell et al., Int. J. Pharm. 66 (1–3), 233–242 (1990).

12. A.R. Rajabi-Siahboomi, A. Nokhodchi, and M.H. Rubinstein, "Compaction Behavior of Hydrophilic Cellulose Ether Polymers," in Pharm. Technol. Yearbook: Tableting and Granulation (1998), pp. 32–40 .

13. R.W. Korsmeyer et al., Int. J. Pharm. 15 (1), 25–35 (1983).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here